Where to buy pratinib

Pralsetinib is a selective RET kinase inhibitor indicated for the treatment of RET-fused cancers (NSCLC) and RET-altered thyroid cancers.

Where to buy Pralsetinib is reliable?

1. Hospital pharmacy purchase

Platinib has been marketed in China, and patients can buy pratinib in hospital pharmacies through a doctor's prescription, which is one of the more routine and reliable ways to buy.

2. Pharmacies or drug retailers

Some pharmacies or drug retailers may offer pratinib, and patients can consult their local pharmacy and purchase pratinib, with a medical prescription required before purchasing.

3. Official channels of pharmaceutical companies

Some pharmaceutical companies may sell pratinib directly, and patients can learn how to purchase it through the pharmaceutical company's official website or customer service channels.

4. Medical service institutions

If you want to buy different versions of pratinib, such as the original drug or a generic drug, you can contact the medical service provider in China to find out which version of pratinib can be purchased and the price.

Efficacy of pratinib in the treatment of thyroid cancer

Gavretto, generically known as pracetinib, is another targeted therapy that has shown promise in the treatment of thyroid cancer. The U.S. Food and Drug Administration has approved its accelerated treatment for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-medullary thyroid cancer (MTC) who require systemic therapy, or RET-fusion-positive thyroid cancer that is refractory to radioiodine and has progressed on prior therapy. Gavreto is a selective RET kinase inhibitor, which means it targets genetic alterations in RET primary genes that drive cancer progression.

Gavreto's clinical trial in patients with RET-driven thyroid cancer reported a high response rate, indicating a reduction in tumor size. In a phase 1/2 trial, Gavreto demonstrated a robust response in patients with RET-piliary medullary thyroid cancer, with the majority of patients experiencing tumor shrinkage. In addition, Gavreto has shown efficacy in patients with RET fusion-positive thyroid cancer, providing a new treatment option for patient populations with limited alternatives.

Overall, Gavreto is not a cure for thyroid cancer patients, but it represents a major advance in the treatment of thyroid cancer with specific genetic variants.